NCT01763021View on ClinicalTrials.gov

A Study to Assess the Effect of Rifampin on the Pharmacokinetics of PCI-32765 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Healthy Participants
Interventions
DRUG

PCI-32765

PCI-32765 will be administered as a single oral dose of PCI-32765 560 mg on Day 1 and Day 11

DRUG

Rifampin

Rifampin 600 mg (2 X 300 mg) daily dose will be administered orally from Day 4 to Day 13 and on Day 11 along with PCI-32765.

Trial Locations (1)

Unknown

Neptune City

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT01763021 - A Study to Assess the Effect of Rifampin on the Pharmacokinetics of PCI-32765 in Healthy Participants | Biotech Hunter | Biotech Hunter